GLP - 1受体激动剂围术期处理的考虑

IF 7.5 1区 医学 Q1 ANESTHESIOLOGY
Anaesthesia Pub Date : 2024-12-17 DOI:10.1111/anae.16524
Glenio B. Mizubuti, Rafael S. F. Nersessian, Leopoldo M. da Silva, Anthony M.-H. Ho
{"title":"GLP - 1受体激动剂围术期处理的考虑","authors":"Glenio B. Mizubuti,&nbsp;Rafael S. F. Nersessian,&nbsp;Leopoldo M. da Silva,&nbsp;Anthony M.-H. Ho","doi":"10.1111/anae.16524","DOIUrl":null,"url":null,"abstract":"<p>We thank Hulst et al. [<span>1</span>] and Levy et al. [<span>2</span>] for their comments on our work [<span>3</span>]. Peri-operative use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has gained much attention recently.</p><p>We acknowledge the significance of power calculations in trial design to minimise type 2 error. It is essential to recognise, however, that power can be considered adequate with a smaller sample size if the effect size is large [<span>4</span>], as evidenced by our observed (clinically significant) differences between semaglutide users (40% incidence of increased residual gastric content) and non-users (3%, p &lt; 0.001). For further clarification, we performed a post hoc power analysis based on our studied patients and parameter estimates. For an effect size of 0.7 based on the presence of increased residual gastric content in 43/107 semaglutide users and 3/113 non-users, and a significance level of 5%, using a χ<sup>2</sup> test, we achieved a critical χ<sup>2</sup> = 11.07 and a power (1-β error probability) &gt; 0.9.</p><p>Our exclusion criteria accounted for conditions known to affect gastric emptying; hence our observed increased residual gastric content can be attributed primarily to semaglutide use. These exclusions strengthen, rather than limit, our findings' applicability. While we did not study patients with diabetes, we agree that future guidelines should focus on peri-operative management of GLP-1 RAs based on their primary use (weight loss vs. diabetes).</p><p>As for other classes of medications that can delay gastric emptying, it is impossible to call for revised societal guidelines for their peri-operative use when such guidelines do not exist. The impaired gastric emptying from these drugs has not been considered sufficiently relevant (unlike that induced by GLP-1 RAs) to warrant the attention of medical or anaesthesia societies to create specific guidelines.</p><p>Recently, several case reports have been published linking peri-operative GLP-1 RA use with bronchoaspiration and/or near misses [<span>5</span>]. Although anecdotal, it would be imprudent to disregard these reports and the growing body of evidence demonstrating a correlation between GLP-1 RA use and increased peri-operative residual gastric content [<span>3, 6</span>] as “<i>lacking evidence</i>” [<span>2</span>]. The recent development of multi-societal guidelines for the peri-operative management of GLP-1 RA [<span>7</span>] reflects this linkage.</p><p>Due to constraints inherent to our institutional protocol, we did not evaluate periods of discontinuation longer than 10 days and, consequently, were unable to make recommendations beyond this timeframe. Nevertheless, based on our findings (and other recent reports [<span>6</span>]), it does appear that 1-week pre-operative discontinuation suggested by the American Society of Anesthesiologists and other medical societies [<span>7</span>] may be insufficient to ensure an empty stomach. Indeed, while previous reports suggesting a 2–3 week semaglutide interruption pre-operatively were based primarily on pharmacologic principles, a recent study by our group suggests that similar intervals are required to reduce/normalise gastric content in semaglutide users [<span>6</span>]. While we acknowledge the limitations of recent reports, they align; therefore, given the catastrophic consequences of bronchoaspiration, it would be prudent to err on the side of caution until more definitive evidence emerges. Additionally, while peri-operative hyperglycaemia resulting from GLP-1 RA interruption remains a subject of debate [<span>8</span>], this can be mitigated by bridging regimens with less/no effect on gastric emptying. Notably, patients with diabetes on GLP-1 RAsare often already on insulin therapy in which case they can simply follow their baseline sliding scale, without the need for further delays (e.g. diabetologist consultation) as suggested by Levy et al. [<span>2</span>].</p><p>Hulst et al. suggested that gastric ultrasound has limited broad application. It is up to clinicians to decide whether this non-invasive tool, which has a rapid learning curve, should be part of their practice. In our cohort, gastric ultrasound prevented unnecessary surgical cancellations in semaglutide users. The peri-operative applicability of gastric ultrasound, particularly in the context of GLP-1 RA use, has gained attention recently and has been highlighted by anaesthesia and medical societies worldwide [<span>7</span>].</p><p>We recognise that ongoing digestive symptoms and semaglutide dosage/therapy duration may impact gastric emptying. Although we did not examine these variables, our study is the largest prospective cohort assessed via peri-operative bedside gastric ultrasound to date. Thus, despite its limitations, our findings are clinically significant.</p>","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"80 3","pages":"340-341"},"PeriodicalIF":7.5000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/anae.16524","citationCount":"0","resultStr":"{\"title\":\"Considerations on peri-operative management of GLP-1 receptor agonists\",\"authors\":\"Glenio B. Mizubuti,&nbsp;Rafael S. F. Nersessian,&nbsp;Leopoldo M. da Silva,&nbsp;Anthony M.-H. Ho\",\"doi\":\"10.1111/anae.16524\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We thank Hulst et al. [<span>1</span>] and Levy et al. [<span>2</span>] for their comments on our work [<span>3</span>]. Peri-operative use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has gained much attention recently.</p><p>We acknowledge the significance of power calculations in trial design to minimise type 2 error. It is essential to recognise, however, that power can be considered adequate with a smaller sample size if the effect size is large [<span>4</span>], as evidenced by our observed (clinically significant) differences between semaglutide users (40% incidence of increased residual gastric content) and non-users (3%, p &lt; 0.001). For further clarification, we performed a post hoc power analysis based on our studied patients and parameter estimates. For an effect size of 0.7 based on the presence of increased residual gastric content in 43/107 semaglutide users and 3/113 non-users, and a significance level of 5%, using a χ<sup>2</sup> test, we achieved a critical χ<sup>2</sup> = 11.07 and a power (1-β error probability) &gt; 0.9.</p><p>Our exclusion criteria accounted for conditions known to affect gastric emptying; hence our observed increased residual gastric content can be attributed primarily to semaglutide use. These exclusions strengthen, rather than limit, our findings' applicability. While we did not study patients with diabetes, we agree that future guidelines should focus on peri-operative management of GLP-1 RAs based on their primary use (weight loss vs. diabetes).</p><p>As for other classes of medications that can delay gastric emptying, it is impossible to call for revised societal guidelines for their peri-operative use when such guidelines do not exist. The impaired gastric emptying from these drugs has not been considered sufficiently relevant (unlike that induced by GLP-1 RAs) to warrant the attention of medical or anaesthesia societies to create specific guidelines.</p><p>Recently, several case reports have been published linking peri-operative GLP-1 RA use with bronchoaspiration and/or near misses [<span>5</span>]. Although anecdotal, it would be imprudent to disregard these reports and the growing body of evidence demonstrating a correlation between GLP-1 RA use and increased peri-operative residual gastric content [<span>3, 6</span>] as “<i>lacking evidence</i>” [<span>2</span>]. The recent development of multi-societal guidelines for the peri-operative management of GLP-1 RA [<span>7</span>] reflects this linkage.</p><p>Due to constraints inherent to our institutional protocol, we did not evaluate periods of discontinuation longer than 10 days and, consequently, were unable to make recommendations beyond this timeframe. Nevertheless, based on our findings (and other recent reports [<span>6</span>]), it does appear that 1-week pre-operative discontinuation suggested by the American Society of Anesthesiologists and other medical societies [<span>7</span>] may be insufficient to ensure an empty stomach. Indeed, while previous reports suggesting a 2–3 week semaglutide interruption pre-operatively were based primarily on pharmacologic principles, a recent study by our group suggests that similar intervals are required to reduce/normalise gastric content in semaglutide users [<span>6</span>]. While we acknowledge the limitations of recent reports, they align; therefore, given the catastrophic consequences of bronchoaspiration, it would be prudent to err on the side of caution until more definitive evidence emerges. Additionally, while peri-operative hyperglycaemia resulting from GLP-1 RA interruption remains a subject of debate [<span>8</span>], this can be mitigated by bridging regimens with less/no effect on gastric emptying. Notably, patients with diabetes on GLP-1 RAsare often already on insulin therapy in which case they can simply follow their baseline sliding scale, without the need for further delays (e.g. diabetologist consultation) as suggested by Levy et al. [<span>2</span>].</p><p>Hulst et al. suggested that gastric ultrasound has limited broad application. It is up to clinicians to decide whether this non-invasive tool, which has a rapid learning curve, should be part of their practice. In our cohort, gastric ultrasound prevented unnecessary surgical cancellations in semaglutide users. The peri-operative applicability of gastric ultrasound, particularly in the context of GLP-1 RA use, has gained attention recently and has been highlighted by anaesthesia and medical societies worldwide [<span>7</span>].</p><p>We recognise that ongoing digestive symptoms and semaglutide dosage/therapy duration may impact gastric emptying. Although we did not examine these variables, our study is the largest prospective cohort assessed via peri-operative bedside gastric ultrasound to date. Thus, despite its limitations, our findings are clinically significant.</p>\",\"PeriodicalId\":7742,\"journal\":{\"name\":\"Anaesthesia\",\"volume\":\"80 3\",\"pages\":\"340-341\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/anae.16524\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anaesthesia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/anae.16524\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/anae.16524","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Considerations on peri-operative management of GLP-1 receptor agonists

We thank Hulst et al. [1] and Levy et al. [2] for their comments on our work [3]. Peri-operative use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has gained much attention recently.

We acknowledge the significance of power calculations in trial design to minimise type 2 error. It is essential to recognise, however, that power can be considered adequate with a smaller sample size if the effect size is large [4], as evidenced by our observed (clinically significant) differences between semaglutide users (40% incidence of increased residual gastric content) and non-users (3%, p < 0.001). For further clarification, we performed a post hoc power analysis based on our studied patients and parameter estimates. For an effect size of 0.7 based on the presence of increased residual gastric content in 43/107 semaglutide users and 3/113 non-users, and a significance level of 5%, using a χ2 test, we achieved a critical χ2 = 11.07 and a power (1-β error probability) > 0.9.

Our exclusion criteria accounted for conditions known to affect gastric emptying; hence our observed increased residual gastric content can be attributed primarily to semaglutide use. These exclusions strengthen, rather than limit, our findings' applicability. While we did not study patients with diabetes, we agree that future guidelines should focus on peri-operative management of GLP-1 RAs based on their primary use (weight loss vs. diabetes).

As for other classes of medications that can delay gastric emptying, it is impossible to call for revised societal guidelines for their peri-operative use when such guidelines do not exist. The impaired gastric emptying from these drugs has not been considered sufficiently relevant (unlike that induced by GLP-1 RAs) to warrant the attention of medical or anaesthesia societies to create specific guidelines.

Recently, several case reports have been published linking peri-operative GLP-1 RA use with bronchoaspiration and/or near misses [5]. Although anecdotal, it would be imprudent to disregard these reports and the growing body of evidence demonstrating a correlation between GLP-1 RA use and increased peri-operative residual gastric content [3, 6] as “lacking evidence” [2]. The recent development of multi-societal guidelines for the peri-operative management of GLP-1 RA [7] reflects this linkage.

Due to constraints inherent to our institutional protocol, we did not evaluate periods of discontinuation longer than 10 days and, consequently, were unable to make recommendations beyond this timeframe. Nevertheless, based on our findings (and other recent reports [6]), it does appear that 1-week pre-operative discontinuation suggested by the American Society of Anesthesiologists and other medical societies [7] may be insufficient to ensure an empty stomach. Indeed, while previous reports suggesting a 2–3 week semaglutide interruption pre-operatively were based primarily on pharmacologic principles, a recent study by our group suggests that similar intervals are required to reduce/normalise gastric content in semaglutide users [6]. While we acknowledge the limitations of recent reports, they align; therefore, given the catastrophic consequences of bronchoaspiration, it would be prudent to err on the side of caution until more definitive evidence emerges. Additionally, while peri-operative hyperglycaemia resulting from GLP-1 RA interruption remains a subject of debate [8], this can be mitigated by bridging regimens with less/no effect on gastric emptying. Notably, patients with diabetes on GLP-1 RAsare often already on insulin therapy in which case they can simply follow their baseline sliding scale, without the need for further delays (e.g. diabetologist consultation) as suggested by Levy et al. [2].

Hulst et al. suggested that gastric ultrasound has limited broad application. It is up to clinicians to decide whether this non-invasive tool, which has a rapid learning curve, should be part of their practice. In our cohort, gastric ultrasound prevented unnecessary surgical cancellations in semaglutide users. The peri-operative applicability of gastric ultrasound, particularly in the context of GLP-1 RA use, has gained attention recently and has been highlighted by anaesthesia and medical societies worldwide [7].

We recognise that ongoing digestive symptoms and semaglutide dosage/therapy duration may impact gastric emptying. Although we did not examine these variables, our study is the largest prospective cohort assessed via peri-operative bedside gastric ultrasound to date. Thus, despite its limitations, our findings are clinically significant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Anaesthesia
Anaesthesia 医学-麻醉学
CiteScore
21.20
自引率
9.30%
发文量
300
审稿时长
6 months
期刊介绍: The official journal of the Association of Anaesthetists is Anaesthesia. It is a comprehensive international publication that covers a wide range of topics. The journal focuses on general and regional anaesthesia, as well as intensive care and pain therapy. It includes original articles that have undergone peer review, covering all aspects of these fields, including research on equipment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信